Essai sur le traitement radioablatif stéréotaxique HYpofractionnéD (HYDRA) du cancer du larynx
Un essai de phase I sur le traitement radioablatif stéréotaxique HYpofractionnéD (HYDRA) du cancer du larynx
To find the highest tolerable dose of stereotactic hypofractionated radioablation (HYDRA) radiation that can be given to patients with laryngeal cancer. The safety of this radiation will also be studied.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
Study Groups:
If participant is found to be eligible to take part in this study, participant will be assigned to a radiation level of HYDRA radiation based on when participant joins this study. Up to 5 dose levels of HYDRA radiation will be tested. Up to 10 participants will be enrolled at each dose level. The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of HYDRA radiation is found.
HYDRA Radiation Administration:
If participant is found to be eligible to take part in this study, participant will receive HYDRA radiation on up to 5 days over the course of about 2 weeks.
During radiation, participant will be asked to lie still for about 30-45 minutes. To help make sure that participant's head and neck do not move, participant will wear a head and neck mask. Participant will then have CT or PET-CT scans to make sure that participant is in the right position before participant begins HYDRA radiation. The actual HYDRA radiation treatment will take about 5-10 minutes to complete.
Length of Study Participation:
Participant may continue receiving HYDRA radiation for up to 2 weeks and for a total of 5 times. Participant will no longer be able to receive the study radiation if the disease gets worse, if intolerable side effects occur, or if participant is unable to follow study directions.
Participation on this study will be over after Long-Term Follow-Up. Long-Term Follow-Up may take up to 10 years.
Study Visits:
On Days that participant receives HYDRA:
- Participant will have a speech pathology exam to check participant's voice, swallowing, and breathing function.
- Participant will complete the same 5 questionnaires that participant did at screening.
Follow-Up Visits:
About 6 weeks after participant's last dose of HYDRA radiation:
- Participant will have a physical exam.
- Participant will have a videostroboscopy to check the status of the disease.
- Participant will have a speech pathology exam.
- Participant will have a CT or PET-CT scan to check the status of the disease.
- Participant will complete the same 5 questionnaires that participant did at screening.
- If the doctor thinks it is needed, participant will have a laryngoscopy to check the status of the disease. A laryngoscopy is a standard procedure in which a tube with a lighted camera is inserted through participant's mouth and into participant's throat.
- If the doctor thinks it is needed, participant will have a core biopsy to check the status of the disease. To perform a core biopsy, a sample of tissue is removed using a hollow core needle that has a cutting edge.
About 3 months after participant's last dose of HYDRA radiation:
- Participant will have a physical exam.
- Participant will have a modified barium swallow to test participant's swallowing function and to check the status of the disease.
- Participant will have a CT or PET-CT scan to check the status of the disease.
- Participant will complete the same 5 questionnaires that participant did at screening.
- If the doctor thinks it is needed, participant will have a laryngoscopy to check the status of the disease.
- If the doctor thinks it is needed, participant will have a core biopsy to check the status of the disease.
About 6 months after participant's last dose of HYDRA radiation:
- Participant will have a physical exam.
- Participant will have a videostroboscopy to check the status of the disease.
- Participant will complete the same 5 questionnaires that participant did at screening.
- If the doctor thinks it is needed, participant will have a CT or PET-CT scan to check the status of the disease.
- If the doctor thinks it is needed, participant will have a speech pathology exam.
- If the doctor thinks it is needed, participant will have a laryngoscopy to check the status of the disease.
- If the doctor thinks it is needed, participant will have a core biopsy to check the status of the disease.
Long-Term Follow-Up:
After participant's 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years:
- Participant will have a physical exam.
- Participant will have a videostroboscopy to check the status of the disease.
- Participant will have a speech pathology exam.
- Participant will have a modified barium swallow to test participant's swallowing function and to check the status of the disease. This will only be done between 3-6 months and then 18-24 months after the first HYDRA dose.
- Participant will complete the same 5 questionnaires that participant did at screening.
- If the doctor thinks it is needed, participant will have a CT or PET-CT scan to check the status of the disease.
- If the doctor thinks it is needed, participant will have a laryngoscopy to check the status of the disease.
- If the doctor thinks it is needed, participant will have a core biopsy to check the status of the disease.
This is an investigational study. HYDRA radiation is delivered using methods that are not FDA-approved or commercially available. It is currently being used for research purposes only. The study doctor can explain how the radiation is designed to work.
Up to 50 participants will be enrolled in this study. All will take part at MD Anderson.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Jack Phan, MD, PHD
- Numéro de téléphone: 713-563-2300
- E-mail: jphan@mdanderson.org
Lieux d'étude
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Recrutement
- MD Anderson Cancer Center
-
Contact:
- Jack Phan, MD,PHD
- E-mail: jphan@mdanderson.org
-
Chercheur principal:
- Jack Phan, MD,PHD
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients older than 18 years of age with histologically proven squamous cell carcinoma of the larynx.
- Stage T1N1/T2-4aN0-1 disease, as defined by American Joint Committee on Cancer (AJCC) criteria.
- ECOG (Zubrod) performance status 0-2.
- Must be functionally and technically fit for partial laryngectomy. Subsite study candidates will be evaluated by enrolling physician. The assessment checklist will be submitted at time of enrollment and evaluated by Dr. Gross or Dr. Phan.
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: *Has not undergone a hysterectomy or bilateral oophorectomy; or *Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
- Ability to understand English language and the willingness to sign a written informed consent.
Exclusion Criteria:
- Patients who have undergone resection of primary disease.
- Patients who have received induction chemotherapy for their cancer diagnosis.
- Patients who have undergone a diverting tracheostomy which is either a) traversing directly through tumor, b) has been placed for true airway insufficiency. Patients with a tracheostomy placed preemptively for impending airway compromise remain eligible for enrollment.
- Prior cancer diagnosis, except appropriately treated localized epithelial skin cancer or cervical cancer.
- Prior radiation therapy to the head and neck region.
- Women of childbearing potential (a woman of child-bearing potential is a reproductively mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months [i.e., who has had menses at any time in the preceding 24 consecutive months]) and male participants must practice effective contraception (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study.
- Patients unable or unwilling to give written, informed consent.
- Severe, active co-morbidity, defined as follows: a. Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months. b. Transmural myocardial infarction within the last 6 months. c. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration. d. Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before registration. e. Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and f. Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. Protocol-specific requirements may also exclude immuno-compromised patients.
- Exclusion #8 continued: g. History of treatment with potent immunosuppressive drugs for such conditions as post organ transplant, severe rheumatoid arthritis, etc. within the past 6 months.
- Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants
- Evidence of metastatic disease
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Stereotactic Hypofractionated Radioablation (HYDRA)
Participants receive HYDRA radiation on up to 5 days over the course of about 2 weeks, and for a total of 5 times. Questionnaires completed at Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years. |
Starting dose is 8.0 Gy per fraction for 5 fractions (total dose = 40.0 Gy). Subsequent cohorts of participants receive an additional 0.5 Gy per fraction.
Autres noms:
Quality of life and symptom questionnaires completed at: Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Maximum Tolerated Dose (MTD) of Stereotactic Hypofractionated RadioAblative (HYDRA) Treatment
Délai: 180 days
|
Toxicity graded using the NCI Common Toxicity Criteria for Adverse Events (CTCAE) v. 4.0. |
180 days
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overall Complete Response Rate of Stereotactic Hypofractionated RadioAblative (HYDRA) Treatment
Délai: 10 years
|
Overall complete response rate with laryngeal HYDRA measured from duration of time from start of treatment to primary disease relapse. |
10 years
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Les enquêteurs
Les enquêteurs
- Chercheur principal: Jack Phan, MD, PHD, M.D. Anderson Cancer Center
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Tumeurs par type histologique
- Tumeurs de la tête et du cou
- Tumeurs, glandulaires et épithéliales
- Carcinome
- Carcinome épidermoïde
- Carcinome épidermoïde de la tête et du cou
- Qualité des soins de santé, accès et évaluation
- Techniques d'investigation
- Méthodes épidémiologiques
- Collecte de données
- Mécanismes d'évaluation des soins de santé
- Qualité des soins de santé
- Santé publique
- Environnement et santé publique
- Enquêtes et questionnaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- 2016-1023
- NCI-2018-01164 (Identificateur de registre: NCI CTRP-Clinical Trials Registry)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .